A Randomized, Endoscopist-Blinded, Prospective Trial to Compare the Efficacy and Patient Tolerability between Bowel Preparation Protocols Using Sodium Picosulfate Magnesium Citrate and Polyethylene-Glycol (1 L and 2 L) for Colonoscopy

Table 4

Comparison between groups: final diagnosis of patients undergone colonoscopy.

Final diagnosis	Preparation			value
	Group A	Group B	Group C
1. Normal	44 (44.4%)	35 (35.4%)	46 (47.4%)	0.203
2. Colon adenoma/cancer	45 (45.5%)	48 (48.5%)	36 (37.1%)	0.252
3. Irritable bowel syndrome	13 (11.0%)	18 (16.8%)	11 (9.9%)	0.351
4. Colonic diverticula	9 (7.6%)	7 (6.5%)	4 (3.6%)	0.371
5. GI hemorrhage	4 (3.4%)	6 (5.6%)	1 (0.9%)	0.170
6. Hemorrhoids	6 (5.1%)	2 (1.9%)	5 (4.5%)	0.350
7. Colitis	6 (5.1%)	4 (3.7%)	5 (4.5%)	0.810
8. Newly diagnosed IBD (UC/CD)	1 (0.8%)	1 (0.9%)	3 (2.7%)	0.436
9. Known IBD (UC/CD)	0 (0.0%)	1 (0.9%)	3 (2.7%)	0.166
10. Others	5 (4.2%)	4 (3.7%)	6 (5.4%)	0.801

1. Normal: includes small hyperplastic polyps approved by pathology; 10. Others: includes gastrointestinal tract lymphoma, melanosis coli, cholecystitis and pancreatic neoplasm, gastric adenoma, or malignancy. Multiple diagnoses per person were possible. GI: gastrointestinal; IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease.